The FDA on May 24, 2019 approved JAKAFIĀ® for steroid-refractory acute Graft-Versus-Host Disease (GVHD) in adult and pediatric patients 12 years and older. JAKAFIĀ® is a product of Incyte Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
